VRN101099, Brain Permeable HER2 Kinase Inhibitor, Shows the Anti-tumor Activity in Preclinical Models of HER2-positive Cancers

被引：0
|
作者：
Ko, Yikyung
Yoo, Jihye
Jung, Hong-Ryul
Lim, Hyerim
Lee, YeongDeok
Kim, Se Hyuk
Shin, Dong Guk
Cho, Serin
Heo, Myung Hoe
Kim, Haelee
Cho, Ha Yeon
Han, Ah Reum
Ko, Eunhwa
Choi, Hwan Geun
Kim, Deakwon
Kim, Sunghwan
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P1-11-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-11-03
引用
收藏
页数：2
相关论文
共 50 条
  • [11] Anti-tumor activity in preclinical models utilizing a conditional bispecific redirected activation molecule (COBRA) targeting Her2
    Stringer, Bradley
    Chouitar, Johara
    Cerbone, Jacqualine
    Fortin, Sarah
    Ainbinder, Alina
    Kysilovsky, Cassie
    Scott, Brittany
    Banerjee, Antara
    CANCER RESEARCH, 2024, 84 (07)
  • [12] Synergistic anti-tumor activity of Nimotuzumab in combination with Trastuzumab in HER2-positive breast cancer
    Yang, Yun
    Guo, Rui
    Tian, Xiaoting
    Zhang, Ziheng
    Zhang, Pengfei
    Li, Changzheng
    Feng, Zhiwei
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2017, 489 (04) : 523 - 527
  • [13] Preclinical characterization of NVL-330, a selective and brain penetrant HER2 tyrosine kinase inhibitor with broad activity on HER2 oncogenic alterations
    Sun, Yuting
    Andrews, Kristin L.
    Tangpeerachaikul, Anupong
    Nguyen, Tuan M.
    Gerard, Baudouin
    Kohl, Nancy E.
    Horan, Joshua C.
    Pelish, Henry E.
    CANCER RESEARCH, 2024, 84 (06)
  • [14] Antitumor activities of EGFR/HER2/HER4 kinase inhibitor S-222611 in the experimental brain metastases of HER2-positive breast cancer
    Hirata, Michinari
    Tanaka, Yukari
    Shinonome, Satomi
    Yamada, Tomomi
    Torii, Mikinori
    Nezasa, Kenichi
    Tanaka, Hidekazu
    CANCER RESEARCH, 2017, 77
  • [15] Tucatinib, a HER2-selective tyrosine kinase inhibitor, increases the anti-tumor activity of trastuzumab antibody-drug conjugates in preclinical models of HER2+breast cancer
    Kulukian, Anita
    Taylor, Janelle
    Olson, Devra
    Zaval, Margo
    Thurman, Robert
    Hengel, Shawna
    Farr, Lauren
    Lewis, Tim S.
    Peterson, Scott R.
    CANCER RESEARCH, 2020, 80 (04)
  • [16] VRN101099: a novel oral treatment option for patients with advanced solid tumors including brain metastasis driven by HER2 amplification or HER2-activating mutations even with T-DXd resistance
    Jung, H. R.
    Ko, Y.
    Yoo, J.
    Kim, S. H.
    Kim, H.
    Seo, K.
    Kim, Y.
    Lee, S.
    Im, H.
    Shin, D.
    Kim, H.
    Kim, J.
    Cho, H. Y.
    Je, S.
    Kim, D.
    Kim, S.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S181 - S181
  • [17] Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
    Yi Ding
    Chang Gong
    De Huang
    Rui Chen
    Pinpin Sui
    Kevin H. Lin
    Gehao Liang
    Lifeng Yuan
    Handan Xiang
    Junying Chen
    Tao Yin
    Peter B. Alexander
    Qian-Fei Wang
    Er-Wei Song
    Qi-Jing Li
    Kris C. Wood
    Xiao-Fan Wang
    Nature Communications, 9
  • [18] Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
    Ding, Yi
    Gong, Chang
    Huang, De
    Chen, Rui
    Sui, Pinpin
    Lin, Kevin H.
    Liang, Gehao
    Yuan, Lifeng
    Xiang, Handan
    Chen, Junying
    Yin, Tao
    Alexander, Peter B.
    Wang, Qian-Fei
    Song, Er-Wei
    Li, Qi-Jing
    Wood, Kris C.
    Wang, Xiao-Fan
    NATURE COMMUNICATIONS, 2018, 9
  • [19] HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
    Olson, Devra
    Taylor, Janelle
    Willis, Kelsi
    Hensley, Kelly
    Allred, Sean
    Zaval, Margo
    Farr, Lauren
    Thurman, Robert
    Jain, Nishi
    Hein, Renee
    Ulrich, Michelle
    Peterson, Scott
    Kulukian, Anita
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (09): : 1927 - 1939
  • [20] ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer
    Barok, Mark
    Le Joncour, Vadim
    Martins, Ana
    Isola, Jorma
    Salmikangas, Marko
    Laakkonen, Pirjo
    Joensuu, Heikki
    CANCER LETTERS, 2020, 473 : 156 - 163
12345